Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 13
Submit an article Journal homepage
417
Views
0
CrossRef citations to date
0
Altmetric
Review

Differing Clinical Impact of BRCA1 and BRCA2 Mutations in Serous Ovarian Cancer

Guoyan Liu1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;2 Department of Gynecology & Obstetrics, Tianjin Medical University General Hospital, Tianjin, ChinaView further author information
,
Da Yang1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Yan Sun1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3 Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, ChinaView further author information
,
Ilya Shmulevich4 Institute for Systems Biology, Seattle, WA, USAView further author information
,
Fengxia Xue2 Department of Gynecology & Obstetrics, Tianjin Medical University General Hospital, Tianjin, ChinaView further author information
,
Anil K Sood5 Department of Cancer Biology & Center for RNAi & Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;6 Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Wei Zhang1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 1523-1535 | Published online: 12 Oct 2012

References

  • Pennington KP , SwisherEM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol. Oncol.124(2) , 347–353 (2012).
  • King MC , MarksJH, MandellJB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302(5645) , 643–646 (2003).
  • Chen S , ParmigianiG. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol.25(11) , 1329–1333 (2007).
  • Sakai W , SwisherEM, KarlanBY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451(7182) , 1116–1120 (2008).
  • Swisher EM , SakaiW, KarlanBY, WurzK, UrbanN, TaniguchiT. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res.68(8) , 2581–2586 (2008).
  • Yang D , KhanS, SunY et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306(14) , 1557–1565 (2011).
  • Hyman DM , ZhouQ, IasonosA et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118(15) , 3703–3709 (2011).
  • Bolton K l, Chenevix-Trench G, Goh C et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA307(4) , 382–390 (2012).
  • Liu J , CristeaMC, FrankelP et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 205(1–2) , 34–41 (2012).
  • Reitsma W , de Bock GH, Oosterwijk JC, Ten Hoor KA, Hollema H, Mourits MJ. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different? Int. J. Gynecol. Cancer22(4) , 579–585 (2012).
  • Whittemore AS , GongG, ItnyreJ. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case–control studies of ovarian cancer. Am. J. Hum. Genet.60(3) , 496–504 (1997).
  • Risch HA , McLaughlinJR, ColeDE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68(3) , 700–710 (2001).
  • Rubin SC , BlackwoodMA, BanderaC et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol.178(4) , 670–677 (1998).
  • Pal T , Permuth-WeyJ, BettsJA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer104(12) , 2807–2816 (2005).
  • Press JZ , De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer8 , 17 (2008).
  • Levine DA , ArgentaPA, YeeCJ et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol. 21(22) , 4222–4227 (2003).
  • Crum CP , DrapkinR, MironA et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin Obstet. Gynecol. 19(1) , 3–9 (2007).
  • Norquist BM , GarciaRL, AllisonKH et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116(22) , 5261–5271 (2010).
  • Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature474(7353) , 609–615 (2011).
  • Bowtell DD . The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer10(11) , 803–808 (2010).
  • Kuo KT , MaoTL, JonesS et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174(5) , 1597–1601 (2009).
  • Jones S , WangTL, Shih Ie M et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science330(6001) , 228–231 (2010).
  • Wiegand KC , ShahSP, Al-AghaOM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med.363(16) , 1532–1543 (2010).
  • Cuatrecasas M , VillanuevaA, Matias-GuiuX, PratJ. K-RAS mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer79(8) , 1581–1586 (1997).
  • Gilks CB , PratJ. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol.40(9) , 1213–1223 (2009).
  • Piek JM , TorrengaB, HermsenB et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam. Cancer 2(2) , 73–78 (2003).
  • Geisler JP , Hatterman-ZoggMA, RatheJA, BullerRE. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl Cancer Inst.94(1) , 61–67 (2002).
  • Hilton JL , GeislerJP, RatheJA, Hattermann-ZoggMA, DeyoungB, BullerRE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl Cancer Inst.94(18) , 1396–1406 (2002).
  • Lim S l, Smith P, Syed N et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br. J. Cancer98(8) , 1452–1456 (2008).
  • Wang Z , LiM, LuS, ZhangY, WangH. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia–BRCA pathway. Cancer Biol. Ther.5(3) , 256–260 (2006).
  • D‘Andrea AD . The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle2(4) , 290–292 (2003).
  • Soegaard M , KjaerSK, CoxM et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin. Cancer Res.14(12) , 3761–3767 (2008).
  • Risch HA , McLaughlinJR, Cole De et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst.98(23) , 1694–1706 (2006).
  • Shaw PA , McLaughlinJR, ZweemerRP et al. Histopathologic features of genetically determined ovarian cancer. Int. J. Gynecol. Pathol. 21(4) , 407–411 (2002).
  • Tan DS , RothermundtC, ThomasK et al. ‘BRCAness‘ syndrome in ovarian cancer: a case–control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26(34) , 5530–5536 (2008).
  • Vencken PM , KriegeM, HoogwerfD et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann. Oncol. 22(6) , 1346–1352 (2011).
  • Gallagher DJ , KonnerJA, Bell-McGuinnKM et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann. Oncol. 22(5) , 1127–1132 (2011).
  • Turner N , TuttA, AshworthA. Hallmarks of ‘BRCAness‘ in sporadic cancers. Nat. Rev. Cancer4(10) , 814–819 (2004).
  • Gourley C , Michie Co, Roxburgh P et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J. Clin. Oncol.28(15) , 2505–2511 (2010).
  • Aida H , TakakuwaK, NagataH et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res. 4(1) , 235–240 (1998).
  • Artioli G , BorgatoL, CappettaA et al. Overall survival in BRCA-associated ovarian cancer: case–control study of an Italian series. Eur. J. Gynaecol. Oncol. 31(6) , 658–661 (2010).
  • Ben David Y , ChetritA, Hirsh-YechezkelG et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J. Clin. Oncol. 20(2) , 463–466 (2002).
  • Boyd J , SonodaY, FedericiMG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283(17) , 2260–2265 (2000).
  • Buller RE , ShahinMS, GeislerJP, ZoggM, De Young BR, Davis CS. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin. Cancer Res.8(5) , 1196–1202 (2002).
  • Cass I , BaldwinRL, VarkeyT, MoslehiR, NarodSA, KarlanBY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer97(9) , 2187–2195 (2003).
  • Chetrit A , Hirsh-YechezkelG, Ben-DavidY, LubinF, FriedmanE, SadetzkiS. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J. Clin .Oncol.26(1) , 20–25 (2008).
  • Hennessy BT , TimmsKM, CareyMS et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28(22) , 3570–3576 (2010).
  • Jóhannsson OT , RanstamJ, BorgA, OlssonH. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol.16(2) , 397–404 (1998).
  • Kringen P , WangY, DumeauxV et al. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer5 , 134 (2005).
  • Lacour RA , WestinSN, MeyerLA et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol. Oncol. 121(2) , 358–363 (2011).
  • Pal T , Permuth-WeyJ, KapoorR, CantorA, SutphenR. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer6(1) , 113–119 (2007).
  • Pharoah PD , EastonDF, StocktonDL, GaytherS, PonderBA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res.59(4) , 868–871 (1999).
  • Ragupathy K , FergusonM. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations. J. Obstet. Gynaecol.31(2) , 178–179 (2011).
  • Ramus SJ , FishmanA, PharoahPD, YarkoniS, AltarasM, PonderBA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur. J. Surg. Oncol.27(3) , 278–281 (2001).
  • Rubin SC , BenjaminI, BehbakhtK et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335(19) , 1413–1416 (1996).
  • Zweemer RP , VerheijenRH, CoeberghJW et al. Survival analysis in familial ovarian cancer, a case control study. Eur. J. Obstet. Gynecol. Reprod. Biol. 98(2) , 219–223 (2001).
  • Dann RB , DeloiaJA, TimmsKM et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol.125(3) , 677–682 (2012).
  • Mankoo PK , ShenR, SchultzN, LevineDA, SanderC. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS ONE6(11) , e24709 (2011).
  • Yarden RI , Pardo-ReoyoS, SgagiasM, CowanKH, BrodyLC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet.30(3) , 285–289 (2002).
  • Joukov V , GroenAC, ProkhorovaT et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 127(3) , 539–552 (2006).
  • Lou Z , Minter-DykhouseK, ChenJ. BRCA1 participates in DNA decatenation. Nat. Struct. Mol. Biol.12(7) , 589–593 (2005).
  • Sankaran S , CroneDE, PalazzoRE, ParvinJD. BRCA1 regulates gamma-tubulin binding to centrosomes. Cancer Biol. Ther.6(12) , 1853–1857 (2007).
  • Starita LM , MachidaY, SankaranS et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol. Cell. Biol. 24(19) , 8457–8466 (2004).
  • Drost R , BouwmanP, RottenbergS et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 20(6) , 797–809 (2011).
  • Narod SA , NeuhausenS, VichodezG et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br. J. Cancer 99(2) , 371–374 (2008).
  • Ferrone CR , LevineDA, TangLH et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J. Clin. Oncol.27(3) , 433–438 (2009).
  • Liede A , KarlanBY, NarodSA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol.22(4) , 735–742 (2004).
  • Hahn SA , GreenhalfB, EllisI et al. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl Cancer Inst.95(3) , 214–221 (2003).
  • Moller P , EvansDG, ReisMM et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int. J. Cancer 121(5) , 1017–1020 (2007).
  • Lee EH , ParkSK, ParkB et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res. Treat. 122(1) , 11–25 (2010).
  • Foulkes WD , MetcalfeK, SunP et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 10(6) , 2029–2034 (2004).
  • Satagopan JM , BoydJ, KauffND et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin. Cancer Res. 8(12) , 3776–3781 (2002).
  • Antoniou A , PharoahPD, NarodS et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5) , 1117–1130 (2003).
  • Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br. J. Cancer83(10) , 1301–1308 (2000).
  • Hall JM , Lee Mk, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science250(4988) , 1684–1689 (1990).
  • Miki Y , SwensenJ, Shattuck-EidensD et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182) , 66–71 (1994).
  • Sy SM , HuenMS, ChenJ. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl Acad. Sci. USA106(17) , 7155–7160 (2009).
  • Wooster R , BignellG, LancasterJ et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559) , 789–792 (1995).
  • Esashi F , ChristN, GannonJ et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434(7033) , 598–604 (2005).
  • Ayoub N , RajendraE, SuX, JeyasekharanAD, MahenR, VenkitaramanAR. The carboxyl terminus of BRCA2 links the disassembly of Rad51 complexes to mitotic entry. Curr. Biol.19(13) , 1075–1085 (2009).
  • Davies OR , PellegriniL. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat. Struct. Mol. Biol.14(6) , 475–483 (2007).
  • Roy R , ChunJ, PowellSN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer12(1) , 68–78 (2011).
  • Lou Z , ChiniCC, Minter-DykhouseK, ChenJ. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J. Biol. Chem.278(16) , 13599–13602 (2003).
  • Hashizume R , FukudaM, MaedaI et al. The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276(18) , 14537–14540 (2001).
  • Jensen RB , CarreiraA, KowalczykowskiSC. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature467(7316) , 678–683 (2010).
  • Holloman WK . Unraveling the mechanism of BRCA2 in homologous recombination. Nat. Struct. Mol. Biol.18(7) , 748–754 (2011).
  • Baumann P , BensonFE, WestSC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell87(4) , 757–766 (1996).
  • Osher DJ , KushnerYB, ArseneauJ, FoulkesWD. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? J. Clin. Pathol.64(10) , 924–926 (2011).
  • Evers B , SchutE, van der Burg E et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res.16(1) , 99–108 (2009).
  • Farmer H , McCabeN, LordCJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035) , 917–921 (2005).
  • Bryant HE , SchultzN, ThomasHD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035) , 913–917 (2005).
  • Chen A . PARP inhibitors: its role in treatment of cancer. Chin. J. Cancer30(7) , 463–471 (2011).
  • Fong PC , BossDS, YapTA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2) , 123–134 (2009).
  • Audeh MW , CarmichaelJ, PensonRT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737) , 245–251 (2010).
  • Fong PC , YapTA, BossDS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28(15) , 2512–2519 (2010).
  • Gelmon KA , TischkowitzM, MackayH et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9) , 852–861 (2011).
  • Kaye SB , LubinskiJ, MatulonisU et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30(4) , 372–379 (2012).
  • Ledermann J , HarterP, GourleyC et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366(15) , 1382–1392 (2012).
  • Turner NC Lord CJ, Iorns E et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J.27(9) , 1368–1377 (2008).
  • Issaeva N , ThomasHD, DjureinovicT et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70(15) , 6268–6276 (2010).
  • Jacquemont C , TaniguchiT. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res.67(15) , 7395–7405 (2007).
  • Deans AJ , KhannaKK, McneesCJ, MercurioC, HeierhorstJ, McarthurGA. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res.66(16) , 8219–8226 (2006).
  • Dungey FA , CaldecottKW, ChalmersAJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol. Cancer Ther.8(8) , 2243–2254 (2009).
  • Chiang JW , KarlanBY, CassL, BaldwinRL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol. Oncol.101(3) , 403–410 (2006).
  • Liu GY , ZhangW. Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? Chin. J. Cancer31(1) , 1–4 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.